Theralase Technologies Inc. (CVE:TLT – Get Free Report) was down 20% during mid-day trading on Tuesday . The stock traded as low as C$0.19 and last traded at C$0.19. Approximately 1,001,827 shares were traded during mid-day trading, an increase of 332% from the average session volume of 231,764 shares. The stock had previously closed at C$0.24.
Theralase Technologies Price Performance
The stock’s 50-day moving average price is C$0.25 and its 200 day moving average price is C$0.27. The firm has a market cap of C$56.18 million, a price-to-earnings ratio of -13.57 and a beta of -0.57. The company has a quick ratio of 3.40, a current ratio of 1.37 and a debt-to-equity ratio of 22.13.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Recommended Stories
- Five stocks we like better than Theralase Technologies
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
